isatuximab key points table.PNG (81.9 kB)

Isatuximab: First Approval

Download (81.9 kB)
online resource
posted on 19.04.2020 by Sohita Dhillon
Compliance with Ethical Standards

Disclosure: The preparation of this review was not supported by any external funding.

Conflict of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found here.

Abstract
Isatuximab (isatuximab-irfc; Sarclisa®) is an IgG1 monoclonal antibody that binds to the glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells. It is being developed by Sanofi, under a license from Immunogen, for the treatment of haematological malignancies. In March 2020, intravenous isatuximab (in combination with pomalidomide and dexamethasone) was approved in the USA for the treatment of adult patients with multiple myeloma who have received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab is also under regulatory review in the EU for the treatment of multiple myeloma. This article summarizes the milestones in the development of isatuximab leading to this first approval.

© Springer Nature Switzerland AG 2020

Read the peer-reviewed publication

Logo branding

Categories

History

Exports

Read the peer-reviewed publication

Logo branding

Categories

Exports